CN110678462B - Mdm2-p53相互作用的异吲哚啉酮抑制剂和其制造方法 - Google Patents

Mdm2-p53相互作用的异吲哚啉酮抑制剂和其制造方法 Download PDF

Info

Publication number
CN110678462B
CN110678462B CN201880022720.4A CN201880022720A CN110678462B CN 110678462 B CN110678462 B CN 110678462B CN 201880022720 A CN201880022720 A CN 201880022720A CN 110678462 B CN110678462 B CN 110678462B
Authority
CN
China
Prior art keywords
alkyl
heterocyclyl
formula
ring members
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880022720.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN110678462A (zh
Inventor
S·霍华德
B·D·康斯
J·D·圣丹尼斯
C·M·格里菲斯-琼斯
S·D·西斯科克
R·S·霍维
A·R·伯恩斯
D·卡森
H·L·德克斯特
G·F·帕拉
J·P·沃茨
R·朱维尔
J·A·斯托克韦尔
K·L·赫斯特
I·A·勒马松
D·J·纳什
J·D·奥斯本
J·C·普列德
N·P·理查兹
A·M·杜马斯
B·C·毕舍普
D·帕瑞-琼斯
J·P·斯科特
M·S·肖恩穆安
P·R·穆伦斯
D·C·拉思伯里
D·J·迪克逊
M·J·冈特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Astex Therapeutics Ltd
Original Assignee
Cancer Research Technology Ltd
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd, Astex Therapeutics Ltd filed Critical Cancer Research Technology Ltd
Publication of CN110678462A publication Critical patent/CN110678462A/zh
Application granted granted Critical
Publication of CN110678462B publication Critical patent/CN110678462B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201880022720.4A 2017-03-28 2018-03-28 Mdm2-p53相互作用的异吲哚啉酮抑制剂和其制造方法 Active CN110678462B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1704965.1A GB201704965D0 (en) 2017-03-28 2017-03-28 Pharmaceutical compounds
GB1704965.1 2017-03-28
PCT/GB2018/050845 WO2018178691A1 (en) 2017-03-28 2018-03-28 Isoindolinone inhibitors of the mdm2-p53 interaction and process for making them

Publications (2)

Publication Number Publication Date
CN110678462A CN110678462A (zh) 2020-01-10
CN110678462B true CN110678462B (zh) 2024-10-29

Family

ID=58687834

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880022720.4A Active CN110678462B (zh) 2017-03-28 2018-03-28 Mdm2-p53相互作用的异吲哚啉酮抑制剂和其制造方法

Country Status (7)

Country Link
US (3) US11603367B2 (enExample)
EP (1) EP3601272A1 (enExample)
JP (1) JP7495790B2 (enExample)
KR (1) KR102673967B1 (enExample)
CN (1) CN110678462B (enExample)
GB (1) GB201704965D0 (enExample)
WO (1) WO2018178691A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
JP2022511437A (ja) * 2018-11-26 2022-01-31 デバイオファーム インターナショナル エス．エー． Ｈｉｖ感染の組み合わせ治療
CN109897069B (zh) * 2019-02-12 2021-08-20 华东师范大学 一种3，3-二取代吲哚啉酮及其衍生物及其合成方法和应用
CN110845288B (zh) * 2019-11-28 2022-07-19 浙江工业大学 一种手性β-氨基醛类化合物的不对称合成方法
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
CN111057128B (zh) * 2019-12-25 2023-05-16 哈尔滨师范大学 一种含硫的异吲哚酮并环肽衍生物及其制备方法
JP2023539867A (ja) 2020-08-27 2023-09-20 大塚製薬株式会社 Ｍｄｍ２アンタゴニストを用いた癌治療に関するバイオマーカー
GB202103080D0 (en) * 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
CN122555699A (zh) * 2023-11-16 2026-08-11 大冢制药株式会社 制备具有抗癌活性的mdm2-p53相互作用的异吲哚啉酮抑制剂的中间体的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009156735A2 (en) * 2008-06-25 2009-12-30 Cancer Research Technology Limited New therapeutic agents
WO2018178691A1 (en) * 2017-03-28 2018-10-04 Astex Therapeutics Limited Isoindolinone inhibitors of the mdm2-p53 interaction and process for making them

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH374071A (de) 1959-04-30 1963-12-31 Geigy Ag J R Verfahren zur Herstellung von neuen Isoindolinderivaten
US3466298A (en) 1967-03-14 1969-09-09 American Home Prod Process for the preparation of 2-(2-aminoethyl)isoindolines
US3763178A (en) 1968-09-05 1973-10-02 American Home Prod Imidazolinyl phenyl carbonyl acid addition salts and related compounds
CY787A (en) 1970-02-12 1976-06-01 American Home Prod Novel phtalimidine compounds
AR203996A1 (es) 1972-03-16 1975-11-12 Rhone Poulenc Sa Procedimiento para preparar derivados de(hidroxi-2-amino-3-propoxi)-3-isoindolinona-1
FR2217000B1 (enExample) 1973-02-08 1976-04-09 Rhone Poulenc Ind
GB1601701A (en) 1977-07-22 1981-11-04 Delmar Chem Production of heterocyclic benzamide compounds
US4200759A (en) 1978-07-20 1980-04-29 Delmar Chemicals, Limited Preparation of imidazo[2,1-a]isoindole compounds
US4244966A (en) 1979-09-24 1981-01-13 American Home Products Corporation 1,3-Dihydro-3-(2-hydroxy-, 2-bromo- or 2-chloroethyl)-2H-isoindol-1-one derivatives
US4312809A (en) 1980-10-31 1982-01-26 E. R. Squibb & Sons, Inc. Lactam derivatives of mercaptoacylamino acids
US4331600A (en) 1980-10-31 1982-05-25 Usv Pharmaceutical Corporation Intermediates for the synthesis of phthalimidines
FR2533563A1 (fr) 1982-09-23 1984-03-30 Adir Nouveaux derives de la sulfonyluree, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
HU212435B (en) 1990-06-07 1996-06-28 Sandoz Ag Herbicidal compositions containing substituted phthalides and heterocyclic phthalides as active ingredient and process for preparation of their active ingredients.
TW448172B (en) 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
DE19807423A1 (de) 1998-02-21 1999-08-26 Hoechst Marion Roussel De Gmbh Subustituierte Isoindolone, ihre Herstellung und ihre Verwendung in Arzneimitteln
EP1199306B1 (en) 1999-07-26 2005-12-07 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
AU1466001A (en) 1999-11-05 2001-05-14 Phase-1 Molecular Toxicology Methods of determining individual hypersensitivity to an agent
DE10134482A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte Isoindole und ihre Verwendung
KR100650966B1 (ko) 2001-12-18 2006-11-30 에프. 호프만-라 로슈 아게 시스-2,4,5-트리페닐-이미다졸린 및 종양 치료에서의 그의용도
FR2840302B1 (fr) 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
CN100548980C (zh) 2002-11-26 2009-10-14 丸石制药株式会社 异吲哚啉衍生物
JP2004217591A (ja) * 2003-01-16 2004-08-05 Dai Ichi Seiyaku Co Ltd シス選択的フルオロシクロプロパン誘導体の製造方法
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
JP2005255660A (ja) 2004-03-10 2005-09-22 Katsuhiko Tomooka 多官能基を有するラクタム類とその製法
JPWO2005095341A1 (ja) 2004-03-30 2007-08-16 協和醗酵工業株式会社 含窒素複素環化合物
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
AU2006216780B8 (en) 2005-02-22 2010-04-22 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and uses thereof
US7705021B2 (en) * 2005-05-02 2010-04-27 Fox Chase Cancer Center Isoindolone compounds, compositions containing the same, and methods of use thereof for the treatment of viral infections related to the etiology of cancer
JP5031745B2 (ja) 2005-08-12 2012-09-26 アストラゼネカ アクチボラグ 代謝型グルタミン酸受容体増強性イソインドロン
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
JPWO2008047831A1 (ja) 2006-10-17 2010-02-25 協和発酵キリン株式会社 Ｊａｋ阻害剤
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
KR20100033981A (ko) 2007-06-03 2010-03-31 벤더르빌트 유니버시티 벤즈아미드 대사성 글루타민산염 수용체5 양성 알로스테릭 조절자 및 이의 제조 및 사용방법
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CA2734363C (en) 2008-09-18 2016-10-25 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
CN104876938A (zh) 2009-11-12 2015-09-02 密歇根大学董事会 螺-吲哚酮mdm2拮抗剂
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
TR201807311T4 (tr) 2011-03-10 2018-06-21 Daiichi Sankyo Co Ltd Dispiropirolidin derivesi.
EP2721007B1 (en) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl isoquinolinone compounds
EP2721008B1 (en) 2011-06-20 2015-04-29 Novartis AG Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
HUE042327T2 (hu) 2011-08-30 2019-06-28 Astex Pharmaceuticals Inc Decitabin-származék készítmények
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
KR101401705B1 (ko) 2012-01-31 2014-06-27 울산대학교 산학협력단 로듐 촉매를 이용한 이소인돌린 유도체의 합성방법
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
PT2914254T (pt) 2012-10-30 2020-04-02 Mei Pharma Inc Terapias de combinação para tratar cancros quimiorresistentes
CN105025884B (zh) 2013-03-01 2019-08-20 阿斯泰克斯制药公司 药物组合
AU2014286237B2 (en) 2013-07-03 2020-08-20 F. Hoffmann-La Roche Ag mRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist
US20160333419A1 (en) 2014-01-14 2016-11-17 Daiichi Sankyo Company, Limited Gene signatures associated with sensitivity to mdm2 inhibitors
AU2015247646B2 (en) 2014-04-17 2019-06-06 The Regents Of The University Of Michigan MDM2 inhibitors and therapeutic methods using the same
JP2017532959A (ja) 2014-10-09 2017-11-09 第一三共株式会社 Ｍｄｍ２阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム
EP3206697A2 (en) 2014-10-17 2017-08-23 Biomirna Holdings Ltd. Lung cancer diagnostics and therapeutics with mir-660
WO2017004538A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
WO2017068412A1 (en) 2015-10-21 2017-04-27 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
US11339448B2 (en) 2018-07-27 2022-05-24 Ottawa Hospital Research Institute Treatment of acute myeloid leukemia
EP3814525A4 (en) 2019-02-24 2022-04-13 Ascentage Pharma (Suzhou) Co., Ltd. TREATMENT METHODS AND BIOMARKERS FOR MDM2 INHIBITORS
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
JP2023539867A (ja) 2020-08-27 2023-09-20 大塚製薬株式会社 Ｍｄｍ２アンタゴニストを用いた癌治療に関するバイオマーカー
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009156735A2 (en) * 2008-06-25 2009-12-30 Cancer Research Technology Limited New therapeutic agents
WO2018178691A1 (en) * 2017-03-28 2018-10-04 Astex Therapeutics Limited Isoindolinone inhibitors of the mdm2-p53 interaction and process for making them

Also Published As

Publication number Publication date
US11603367B2 (en) 2023-03-14
US20210101887A1 (en) 2021-04-08
JP7495790B2 (ja) 2024-06-05
GB201704965D0 (en) 2017-05-10
CN110678462A (zh) 2020-01-10
US20250074900A1 (en) 2025-03-06
KR20190133190A (ko) 2019-12-02
KR102673967B1 (ko) 2024-06-12
EP3601272A1 (en) 2020-02-05
US12077526B2 (en) 2024-09-03
WO2018178691A1 (en) 2018-10-04
JP2020515546A (ja) 2020-05-28
US20230278989A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
JP7566806B2 (ja) 抗がん活性を有するｍｄｍ２－ｐ５３相互作用のイソインドリノン阻害剤
KR102673967B1 (ko) Mdm2-p53 상호작용의 아이소인돌린온 저해제 및 이를 제조하는 방법
KR102743663B1 (ko) 항암 활성을 갖는 mdm2-p53 상호작용의 아이소인돌리논 저해제
HK40088238A (en) Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
RU2794333C1 (ru) Изоиндолиноновые ингибиторы взаимодействия mdm2-p53, обладающие противораковой активностью
HK40082646A (en) Intermediates of isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
HK1250715B (en) Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
NZ740737B2 (en) Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
BR112018005936B1 (pt) Inibidores de isoindolinona da interação de mdm2-p53, composição farmacêutica, seus usos e processo para a preparação do composto

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant